Cargando…
Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive mammary epithelial tumor characterized by the lack of expression for estrogen receptors and progesterone receptors, and the absence of epidermal growth factor receptor (HER)2 amplification. Corresponding to 15–20% of a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378597/ https://www.ncbi.nlm.nih.gov/pubmed/37510134 http://dx.doi.org/10.3390/diagnostics13142390 |
_version_ | 1785079807342542848 |
---|---|
author | Matou-Nasri, Sabine Aldawood, Maram Alanazi, Fatimah Khan, Abdul Latif |
author_facet | Matou-Nasri, Sabine Aldawood, Maram Alanazi, Fatimah Khan, Abdul Latif |
author_sort | Matou-Nasri, Sabine |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive mammary epithelial tumor characterized by the lack of expression for estrogen receptors and progesterone receptors, and the absence of epidermal growth factor receptor (HER)2 amplification. Corresponding to 15–20% of all breast cancers and well-known by its poor clinical outcome, this negative receptor expression deprives TNBC from targeted therapy and makes its management therapeutically challenging. Type 2 diabetes mellitus (T2DM) is the most common ageing metabolic disorder due to insulin deficiency or resistance resulting in hyperglycemia, hyperinsulinemia, and hyperlipidemia. Due to metabolic and hormonal imbalances, there are many interplays between both chronic disorders leading to increased risk of breast cancer, especially TNBC, diagnosed in T2DM patients. The purpose of this review is to provide up-to-date information related to epidemiology and clinicopathological features, risk factors, diagnosis, biomarkers, and current therapy/clinical trials for TNBC patients with T2DM compared to non-diabetic counterparts. Thus, in-depth investigation of the diabetic complications on TNBC onset, development, and progression and the discovery of biomarkers would improve TNBC management through early diagnosis, tailoring therapy for a better outcome of T2DM patients diagnosed with TNBC. |
format | Online Article Text |
id | pubmed-10378597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103785972023-07-29 Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy Matou-Nasri, Sabine Aldawood, Maram Alanazi, Fatimah Khan, Abdul Latif Diagnostics (Basel) Review Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive mammary epithelial tumor characterized by the lack of expression for estrogen receptors and progesterone receptors, and the absence of epidermal growth factor receptor (HER)2 amplification. Corresponding to 15–20% of all breast cancers and well-known by its poor clinical outcome, this negative receptor expression deprives TNBC from targeted therapy and makes its management therapeutically challenging. Type 2 diabetes mellitus (T2DM) is the most common ageing metabolic disorder due to insulin deficiency or resistance resulting in hyperglycemia, hyperinsulinemia, and hyperlipidemia. Due to metabolic and hormonal imbalances, there are many interplays between both chronic disorders leading to increased risk of breast cancer, especially TNBC, diagnosed in T2DM patients. The purpose of this review is to provide up-to-date information related to epidemiology and clinicopathological features, risk factors, diagnosis, biomarkers, and current therapy/clinical trials for TNBC patients with T2DM compared to non-diabetic counterparts. Thus, in-depth investigation of the diabetic complications on TNBC onset, development, and progression and the discovery of biomarkers would improve TNBC management through early diagnosis, tailoring therapy for a better outcome of T2DM patients diagnosed with TNBC. MDPI 2023-07-17 /pmc/articles/PMC10378597/ /pubmed/37510134 http://dx.doi.org/10.3390/diagnostics13142390 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Matou-Nasri, Sabine Aldawood, Maram Alanazi, Fatimah Khan, Abdul Latif Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy |
title | Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy |
title_full | Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy |
title_fullStr | Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy |
title_full_unstemmed | Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy |
title_short | Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy |
title_sort | updates on triple-negative breast cancer in type 2 diabetes mellitus patients: from risk factors to diagnosis, biomarkers and therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378597/ https://www.ncbi.nlm.nih.gov/pubmed/37510134 http://dx.doi.org/10.3390/diagnostics13142390 |
work_keys_str_mv | AT matounasrisabine updatesontriplenegativebreastcancerintype2diabetesmellituspatientsfromriskfactorstodiagnosisbiomarkersandtherapy AT aldawoodmaram updatesontriplenegativebreastcancerintype2diabetesmellituspatientsfromriskfactorstodiagnosisbiomarkersandtherapy AT alanazifatimah updatesontriplenegativebreastcancerintype2diabetesmellituspatientsfromriskfactorstodiagnosisbiomarkersandtherapy AT khanabdullatif updatesontriplenegativebreastcancerintype2diabetesmellituspatientsfromriskfactorstodiagnosisbiomarkersandtherapy |